Targets › GYRB
8 programs from 8 companies in 9 trials: 4 Phase 2, 3 Phase 4, 1 Phase 3, 1 Phase 1; Infectious disease, Ophthalmology, Respiratory; next expected readout Nov 2026.
Open in Phaseline: the race on GYRB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kazakh Eye Research Institute | Picloxidine DNA gyrase inhibitor (broad-spectrum antimicrobial agent) | GYRB | Phase 4 | Neonatal Dacryocystitis | Nov 2026 |
| Assiut University | Levofloxacin DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRA, GYRB | Phase 4 | Bronchiectasis With Acute Exacerbation | Feb 2027 |
| Mahidol University | Levofloxacin DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRA, GYRB | Phase 4 | Bacteremia | Dec 2027 |
| Laboratorios Sophia S.A de C.V. | Moxifloxacin (PRO-232) Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor | GYRB, NR3C1 | Phase 3 | Cataract Extraction | – |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | Levofloxacin DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRB, RNAP | Phase 2 | Tuberculosis Infection, Latent | Apr 2027 |
| Copenhagen Respiratory Research | Levofloxacin DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRA, GYRB | Phase 2 | Community-acquired Pneumonia; Community Acquired Pneumonia (CAP) | Sep 2028 |
| Al-Mustafa University College | Ciprofloxacin Bacterial DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRB | Phase 2 | Cutaneous Leishmaniasis | – |
| National University Hospital, Singapore | Ciprofloxacin Bacterial DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRA, GYRB | Phase 1 | Metastatic Pancreatic Ductal Adenocarcinoma | Feb 2027 |
Neonatal Dacryocystitis (1) Tuberculosis Infection, Latent (1) Bronchiectasis With Acute Exacerbation (1) Cataract Extraction (1) Cutaneous Leishmaniasis (1) Community-acquired Pneumonia (1) Community Acquired Pneumonia (CAP) (1) Metastatic Pancreatic Ductal Adenocarcinoma (1) Bacteremia (1)
small molecule (8)
Kazakh Eye Research Institute (1) McGill University Health Centre/Research Institute of the McGill University Health Centre (1) Assiut University (1) Laboratorios Sophia S.A de C.V. (1) Al-Mustafa University College (1) Copenhagen Respiratory Research (1) National University Hospital, Singapore (1) Mahidol University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.